As Filed with the Securities and Exchange Commission on December 5, 2008

Registration No. 001-34154

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

AMENDMENT NO. 7

TO

FORM 10

 

GENERAL FORM FOR REGISTRATION OF SECURITIES

Pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934

 

 

Facet Biotech Corporation

 (Exact name of registrant as specified in its charter)

 

Delaware

 

26-2940575

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification No.)

 

 

 

1400 Seaport Boulevard, Redwood City, CA

 

94063

(Address of principal executive offices)

 

(Zip Code)

 

(650) 454-1000

(Registrant’s telephone number, including area code)

 

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Name of Each Exchange on Which

to be so Registered

 

Each Class is to be Registered

 

 

 

Common Stock, par value $0.01 per share

 

NASDAQ Global Market

 

Securities to be registered pursuant to Section 12(g) of the Act

None

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer o

 

Accelerated filer x

 

 

 

Non-accelerated filer   o  (Do not check if a smaller reporting company)

 

Smaller reporting company o

 

 

 


 

INFORMATION REQUIRED IN REGISTRATION STATEMENT

 

CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10

 

Our information statement is filed as Exhibit 99.1 to this Form 10. For your convenience, we have provided below a cross-reference sheet identifying where the items required by Form 10 can be found in the information statement.

 

Item No.

 

Caption

 

Location in Information Statement

1.

 

Business

 

“Summary”, “Risk Factors”, “The Spin-Off”, “Our Business”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, “Where to Obtain More Information”

 

 

 

 

 

1A.

 

Risk Factors

 

“Risk Factors”

 

 

 

 

 

2.

 

Financial Information

 

“Historical Selected Financial Data”, “Unaudited Pro Forma Condensed Combined Balance Sheet”,“Capitalization”, and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”

 

 

 

 

 

3.

 

Properties

 

“Our Business”, and “Our Relationship with PDL after the Spin-Off”,

 

 

 

 

 

4.

 

Security Ownership of Certain Beneficial Owners and Management

 

“Security Ownership of Certain Beneficial Owners and Management”

 

 

 

 

 

5.

 

Directors and Executive Officers

 

“Management”, and “Board of Directors”

 

 

 

 

 

6.

 

Executive Compensation

 

“Compensation Discussion and Analysis”

 

 

 

 

 

7.

 

Certain Relationships and Related Transactions and Director Independence

 

“Security Ownership of Certain Beneficial Owners and Management”, “Related Person Transactions”, and “Our Relationship with PDL after the Spin-Off”, “Board of Directors”

 

 

 

 

 

8.

 

Legal Proceedings

 

“Our Business”

 

 

 

 

 

9.

 

Market Price of Dividends on Registrant’s Common Equity and Related Stockholder Matters

 

“The Spin-Off,” “Dividend Policy”, “Description of Capital Stock”, and “Compensation Discussion and Analysis”

 

 

 

 

 

10.

 

Recent Sales of Unregistered Securities

 

Not Applicable

 

 

 

 

 

11.

 

Description of Registrant’s Securities to be Registered

 

“The Spin-Off”, “Dividend Policy” and “Description of Capital Stock”

 

 

 

 

 

12.

 

Indemnification of Directors and Officers

 

“Indemnification of Directors and Officers”

 

2


 

Item No.

 

Caption

 

Location in Information Statement

13.

 

Financial Statements and Supplementary Data

 

“Historical Selected Financial Data”, and “Unaudited Pro Forma Condensed Combined Balance Sheet”

 

 

 

 

 

14.

 

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

Not Applicable

 

 

 

 

 

15.

 

Financial Statements and Exhibits

 

See “Index to Combined Financial Statements” and the statements referenced therein

 

(a)  Financial Statements

 

The information required by this item is contained in the “Unaudited Pro Forma Financial Statements” and “Index to Financial Statements” and the statements referenced therein and is incorporated herein by reference.

 

(b)  Exhibits

 

The following documents are filed as exhibits hereto:

 

Exhibit No.

 

Exhibit

 

 

 

2.1

 

Form of Separation and Distribution Agreement by and between Facet Biotech Corporation and PDL BioPharma, Inc.**

 

 

 

3.1

 

Amended and Restated Certificate of Incorporation of Facet Biotech Corporation**

 

 

 

3.2

 

Bylaws of Facet Biotech Corporation**

 

 

 

4.1

 

Specimen Stock Certificate of Facet Biotech Corporation**

 

 

 

10.1

 

Form of Transition Services Agreement by and between Facet Biotech Corporation and PDL BioPharma, Inc.**

 

 

 

10.2

 

Form of Tax Sharing and Indemnification Agreement by and between Facet Biotech Corporation and PDL BioPharma, Inc.**

 

 

 

*10.3

 

2008 Equity Incentive Plan**

 

 

 

*10.4

 

Form of Notice of Grant of Stock Option under the 2008 Equity Incentive Plan**

 

 

 

*10.5

 

Form of Stock Option Agreement under the 2008 Equity Incentive Plan**

 

 

 

*10.6

 

Forms of Notice of Grant of Restricted Stock Award under the 2008 Equity Incentive Plan**

 

 

 

*10.7

 

Form of Restricted Stock Agreement under the 2008 Equity Incentive Plan**

 

 

 

*10.8

 

Retention and Severance Plan**

 

 

 

*10.9

 

Form of Indemnity Agreement**

 

 

 

*10.10

 

Form of Offer Letter between Facet Biotech Corporation and Faheem Hasnain**

 

 

 

*10.11

 

2008 Performance Bonus Program**

 

 

 

10.12

 

Triple Net Space Lease, effective July 6, 2006, between Pacific Shores Investors, LLC and PDL BioPharma, Inc. (for building located at 1400 Seaport Boulevard, Redwood City, California)**

 

3


 

10.13

 

Triple Net Space Lease, effective July 6, 2006, between the Pacific Shores Investors, LLC and PDL BioPharma, Inc. (for building located at 1500 Seaport Boulevard, Redwood City, California)**

 

 

 

10.14

 

Sublease, effective July 6, 2006, between Openwave Systems, Inc. and PDL BioPharma, Inc. (for building located at 1400 Seaport Boulevard, Redwood City, California)**

 

 

 

10.15

 

Collaboration Agreement dated as of September 12, 2005 by and between PDL BioPharma, Inc. and Biogen Idec MA Inc. and First Amendment to Collaboration Agreement dated as of November 1, 2007.†**

 

 

 

10.16

 

License Agreement dated as of December 15, 2005 by and between Protein Design Labs, Inc. and Human Genome Sciences, Inc.†**

 

 

 

10.17

 

Asset Purchase Agreement dated as of February 4, 2008 by and between PDL BioPharma, Inc. and EKR Therapeutics, Inc. and Amendment No. 1 to Asset Purchase Agreement dated as of March 7, 2008.†**

 

 

 

10.18

 

Clinical Drug Substance Supply Agreement, effective March 13, 2008, between PDL BioPharma, Inc. and GMN, Inc.†**

 

 

 

10.19

 

Collaboration Agreement dated as of August 18, 2008 by and between PDL BioPharma, Inc. and Bristol-Myers Squibb Company†**

 

 

 

21.1

 

Subsidiaries of Facet Biotech Corporation**

 

 

 

99.1

 

Information Statement of Facet Biotech Corporation, dated December 10, 2008

 

*                               Management contract or compensatory plan or arrangement.

**                        Previously filed.

***                 To be filed by amendment.

†                                Certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request under 17 C.F.R. Sections 200.80(b)(4) and 24b-2.

 

4


 

SIGNATURES

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the registrant caused this amendment to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Facet Biotech Corporation

 

 

Date: December 5, 2008

By:

  /s/ Andrew Guggenhime

 

 

  Andrew Guggenhime

 

 

  Chief Financial Officer

 

5


 

INDEX TO EXHIBITS

 

Exhibit No.

 

Exhibit

 

 

 

2.1

 

Form of Separation and Distribution Agreement by and between Facet Biotech Corporation and PDL BioPharma, Inc.**

 

 

 

3.1

 

Amended and Restated Certificate of Incorporation of Facet Biotech Corporation**

 

 

 

3.2

 

Bylaws of Facet Biotech Corporation**

 

 

 

4.1

 

Specimen Stock Certificate of Facet Biotech Corporation**

 

 

 

10.1

 

Form of Transition Services Agreement by and between Facet Biotech Corporation and PDL BioPharma, Inc.**

 

 

 

10.2

 

Form of Tax Sharing and Indemnification Agreement by and between Facet Biotech Corporation and PDL BioPharma, Inc.**

 

 

 

*10.3

 

2008 Equity Incentive Plan**

 

 

 

*10.4

 

Form of Notice of Grant of Stock Option under the 2008 Equity Incentive Plan**

 

 

 

*10.5

 

Form of Stock Option Agreement under the 2008 Equity Incentive Plan**

 

 

 

*10.6

 

Forms of Notice of Grant of Restricted Stock Award under the 2008 Equity Incentive Plan**

 

 

 

*10.7

 

Form of Restricted Stock Agreement under the 2008 Equity Incentive Plan**

 

 

 

*10.8

 

Retention and Severance Plan**

 

 

 

*10.9

 

Form of Indemnity Agreement**

 

 

 

*10.10

 

Form of Offer Letter between Facet Biotech Corporation and Faheem Hasnain**

 

 

 

*10.11

 

2008 Performance Bonus Program**

 

 

 

10.12

 

Triple Net Space Lease, effective July 6, 2006, between Pacific Shores Investors, LLC and PDL BioPharma, Inc. (for building located at 1400 Seaport Boulevard, Redwood City, California)**

 

 

 

10.13

 

Triple Net Space Lease, effective July 6, 2006, between the Pacific Shores Investors, LLC and PDL BioPharma, Inc. (for building located at 1500 Seaport Boulevard, Redwood City, California)**

 

 

 

10.14

 

Sublease, effective July 6, 2006, between Openwave Systems, Inc. and PDL BioPharma, Inc. (for building located at 1400 Seaport Boulevard, Redwood City, California)**

 

 

 

10.15

 

Collaboration Agreement dated as of September 12, 2005 by and between PDL BioPharma, Inc. and Biogen Idec MA Inc. and First Amendment to Collaboration Agreement dated as of November 1, 2007.†**

 

 

 

10.16

 

License Agreement dated as of December 15, 2005 by and between Protein Design Labs, Inc. and Human Genome Sciences, Inc.†**

 

 

 

10.17

 

Asset Purchase Agreement dated as of February 4, 2008 by and between PDL BioPharma, Inc. and EKR Therapeutics, Inc. and Amendment No. 1 to Asset Purchase Agreement dated as of March 7, 2008.†**

 

 

 

10.18

 

Clinical Drug Substance Supply Agreement, effective March 13, 2008, between PDL BioPharma, Inc. and GMN, Inc.†**

 

6


 

10.19

 

Collaboration Agreement dated as of August 18, 2008 by and between PDL BioPharma, Inc. and Bristol-Myers Squibb Company†**

 

 

 

21.1

 

Subsidiaries of Facet Biotech Corporation**

 

 

 

99.1

 

Information Statement of Facet Biotech Corporation, dated December 10, 2008

 

*

 

Management contract or compensatory plan or arrangement.

**

 

Previously filed.

***

 

To be filed by amendment.

†

 

Certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request under 17 C.F.R. Sections 200.80(b)(4) and 24b-2.

 

7